GLP1R and MODY: An alternative to sulfonylureas is glucagon-like peptide-1 receptor agonist (GLP-1RA), such as dulaglutide, semaglutide, and liraglutide, which are glucose dependent and possess broad efficacy.10While knowledge of GLP-1RA use in MODY is currently limited, these agents have demonstrated potential in reducing hypoglycemia, improving cardiovascular risk factors, and holding promise for specific MODY phenotypes likeHNF1A-MODY.